The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Open accessAbstract
We have previously shown that a thickened cell wall is responsible for the vancomycin resistance of vancomycin-resistant Staphylococcus aureus (VRSA) (equivalent to vancomycin-intermediate S. aureus and glycopeptide-intermediate S. aureus ) strain Mu50 (L. Cui, H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu, Antimicrob. Agents Chemother. 44:2276-2285, 2000). However, the mechanism of vancomycin resistance in other VRSA strains remained unclear. In this study, 16 clinical VRSA strains from seven countries were subjected to serial daily passage in drug-free medium. After 10 to 84 days of passage in the nonselective medium, passage-derived strains with decreased MICs of vancomycin (MIC, <4 mg/liter) were obtained. However, all of the passage-derived strains except one (15 of 16) still possessed subpopulations that were resistant to vancomycin as judged by population analysis, and vancomycin-resistant mutant strains were selected from the passage-derived strains by one-step vancomycin selection with a frequency of 4.25 × 10 −6 to 1.64 × 10 −3 . The data indicated that vancomycin-resistant cells are frequently generated from the passage-derived strains even after vancomycin selective pressure is lifted. Cell wall thicknesses and MICs of glycopeptides (vancomycin and teicoplanin) and beta-lactams (imipenem and oxacillin) were determined for a total of 48 strains, including 15 sets of three strains: the clinical VRSA strain, the passage-derived strain, and the vancomycin-resistant mutant strain obtained from the passage-derived strain. No simple correlation between glycopeptide and beta-lactam MICs was seen, while significant correlations between MICs of vancomycin and teicoplanin ( r = 0.679; P < 0.001) and between MICs of imipenem and oxacillin ( r = 0.787; P < 0.001) were recognized. Moreover, all of the VRSA strains had significantly thickened cell walls, which became thinner with the loss of vancomycin resistance during drug-free passages and again became thick in the resistant mutant strains. The data showed that cell wall thickness had high correlation with the MICs of the two glycopeptides (correlation coefficients, 0.908 for vancomycin and 0.655 for teicoplanin) but not with those of the beta-lactam antibiotics tested. These results together with coupled changes of cell wall thickness and vancomycin MICs in 16 isogenic sets of strains indicate that thickening of the cell wall is a common phenotype of clinical VRSA strains and may be a phenotypic determinant for vancomycin resistance in S. aureus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These strains exhibit excessive peptidoglycan synthesis, leading to increased cell wall density, which sequesters vancomycin molecules before they can reach their targets [215,216].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H., & Swaminathan, B. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2233-2239.1995 · Cited by 8,204
Self-citationHiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Self-citationEmergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Self-citationUse of the Cell Wall Precursor Lipid II by a Pore-Forming Peptide Antibiotic
Breukink, E., Wiedemann, I., Kraaij, C. V., Kuipers, O. P., Sahl, H.-G., & de Kruijff, B. (1999) · Science · doi:10.1126/science.286.5448.2361 · Cited by 814
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Self-citationSieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Self-citationTenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Self-citationHanaki, H. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.199 · Cited by 366
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
Self-citationCui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H., & Hiramatsu, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2276-2285.2000 · Cited by 318
Self-citationWeinstein, R. A., & Fridkin, S. K. (2001) · Clinical Infectious Diseases · doi:10.1086/317542 · Cited by 304
Vancomycin resistance in staphylococci
Hiramatsu, K. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80029-0 · Cited by 227
Self-citationThe emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
Hiramatsu, K. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00149-1 · Cited by 191
Self-citationHanaki, H., Labischinski, H., Inaba, Y., Kondo, N., Murakami, H., & Hiramatsu, K. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.3.315 · Cited by 173
Self-citationInactivated pbp4 in Highly Glycopeptide-resistant Laboratory Mutants of Staphylococcus aureus
Sieradzki, K., Pinho, M. G., & Tomasz, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.18942 · Cited by 153
Vancomycin-Intermediate Staphylococcus aureus in Korea
Kim, M., Pai, C. H., Woo, J. H., Ryu, J. S., & Hiramatsu, K. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.10.3879-3881.2000 · Cited by 142
Self-citationReversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates
Boyle‐Vavra, S., Berke, S. K., Lee, J. C., & Daum, R. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.272-277.2000 · Cited by 126
Boyle‐Vavra, S., Labischinski, H., Ebert, C. C., Kerstin Ehlert, B., & Daum, R. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.280-287.2001 · Cited by 118
Isolation in Brazil of NosocomialStaphylococcus aureusWith Reduced Susceptibility to Vancomycin
Oliveira, G. A., Dell'aquila, A., Masiero, R. L., Levy, C. E., Gomes, M. S., Cui, L., Hiramatsu, K., & Mamizuka, E. M. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501932 · Cited by 118
Self-citationConversion of Oxacillin-Resistant Staphylococci from Heterotypic to Homotypic Resistance Expression
Finan, J. E., Rosato, A. E., Dickinson, T. M., Ko, D., & Archer, G. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.24-30.2002 · Cited by 76
Chesneau, O., Morvan, A., & Solh, N. E. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.6.887 · Cited by 65
Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin
Wong, S. S. Y., Ng, T. K., Yam, W.-C., Tsang, D. N., Woo, P. C. Y., Fung, S. K. S., & Yuen, K. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00141-8 · Cited by 57
Reynolds, P. E., & Somner, E. A. (1990) · PubMed · Cited by 56
Vancomycin-Intermediate Staphylococcus aureus in a Home Health-Care Patient
Hageman, J. C., Pegues, D. A., Jepson, C., Bell, R. L., Guinan, M. E., Ward, K. W., Cohen, M. D., Hindler, J. A., Tenover, F. C., McAllister, S. K., et al. (2001) · Emerging infectious diseases · doi:10.3201/eid0706.010618 · Cited by 55
Self-citationAritaka, N., Hanaki, H., Cui, L., & Hiramatsu, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1292-1294.2001 · Cited by 42
Self-citationA case of vancomycin-resistant enterococcal endocarditis.
Ferraz, V., Dusé, A. G., Kassel, M., Black, A. D., Ito, T., & Hiramatsu, K. (2000) · PubMed · Cited by 39
Self-citation
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Coagulase-Negative Staphylococci
Becker, K., Heilmann, C., & Peters, G. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-13 · Cited by 1,628
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Metadata
- Authors
- Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., Ferraz, V., & Hiramatsu, K.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2003-01
- Volume
- 41
- Issue
- 1
- Pages
- 5-14
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2165562761
- Cited by
- 492
- References
- 27
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.